Encompass Health (NYSE:EHC) Given Strong-Buy Rating at Raymond James

Raymond James restated their strong-buy rating on shares of Encompass Health (NYSE:EHC) in a report released on Friday morning, Benzinga reports. They currently have a $95.00 target price on the stock, up from their prior target price of $85.00.

EHC has been the subject of a number of other reports. Barclays upped their price target on shares of Encompass Health from $101.00 to $108.00 and gave the company an overweight rating in a report on Thursday. Truist Financial boosted their price objective on shares of Encompass Health from $82.00 to $86.00 and gave the company a buy rating in a research report on Friday, February 9th. Mizuho boosted their price objective on shares of Encompass Health from $93.00 to $95.00 and gave the company a buy rating in a research report on Thursday. Stephens reissued an overweight rating and set a $85.00 price objective on shares of Encompass Health in a research report on Tuesday, January 16th. Finally, William Blair reissued an outperform rating on shares of Encompass Health in a research report on Wednesday, February 7th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Buy and a consensus price target of $86.56.

Encompass Health Trading Down 0.3 %

NYSE:EHC opened at $82.46 on Friday. The company has a fifty day moving average of $78.25 and a 200 day moving average of $70.87. Encompass Health has a 52 week low of $57.55 and a 52 week high of $85.84. The company has a quick ratio of 1.28, a current ratio of 1.37 and a debt-to-equity ratio of 1.14. The firm has a market capitalization of $8.26 billion, a P/E ratio of 22.29, a P/E/G ratio of 1.50 and a beta of 0.94.

Encompass Health (NYSE:EHC) last posted its quarterly earnings results on Wednesday, April 24th. The company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.19. Encompass Health had a net margin of 7.60% and a return on equity of 18.01%. The company had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.27 billion. During the same period in the prior year, the business posted $0.88 EPS. The firm’s revenue was up 13.4% compared to the same quarter last year. On average, research analysts predict that Encompass Health will post 4.04 earnings per share for the current year.

Encompass Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Monday, April 1st were given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date was Thursday, March 28th. Encompass Health’s dividend payout ratio is presently 16.22%.

Institutional Trading of Encompass Health

Several institutional investors have recently bought and sold shares of the company. New York State Teachers Retirement System grew its position in Encompass Health by 6.8% during the 1st quarter. New York State Teachers Retirement System now owns 73,166 shares of the company’s stock valued at $6,042,000 after purchasing an additional 4,670 shares during the last quarter. Horrell Capital Management Inc. grew its position in Encompass Health by 0.5% during the 1st quarter. Horrell Capital Management Inc. now owns 29,371 shares of the company’s stock valued at $2,425,000 after purchasing an additional 147 shares during the last quarter. Equitable Trust Co. grew its position in Encompass Health by 69.4% during the 1st quarter. Equitable Trust Co. now owns 6,429 shares of the company’s stock valued at $531,000 after purchasing an additional 2,634 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Encompass Health by 75.7% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 720,173 shares of the company’s stock valued at $59,472,000 after purchasing an additional 310,285 shares during the last quarter. Finally, Rice Hall James & Associates LLC grew its position in Encompass Health by 15.1% during the 1st quarter. Rice Hall James & Associates LLC now owns 55,111 shares of the company’s stock valued at $4,551,000 after purchasing an additional 7,225 shares during the last quarter. 97.25% of the stock is owned by hedge funds and other institutional investors.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.